These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 12206979)
1. [Cured from Hodgkin's disease]. Brice P Bull Cancer; 2002; 89(7-8):666-70. PubMed ID: 12206979 [TBL] [Abstract][Full Text] [Related]
2. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute. Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748 [TBL] [Abstract][Full Text] [Related]
3. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center]. Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222 [TBL] [Abstract][Full Text] [Related]
4. Hodgkin's disease: summary of twenty years' experience. Mazza P; Bocchia M; Zinzani PL; Fiacchini M; Gherlinzoni F; Bandini G; Bendandi M; Frezza GP; Neri S; Barbieri E Haematologica; 1992; 77(6):487-93. PubMed ID: 1283856 [TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of survival in Hodgkin's lymphoma. Canellos GP; Niedzwiecki D; Johnson JL N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568 [No Abstract] [Full Text] [Related]
6. Hodgkin's disease and the risk of acute leukemia in successfully treated patients. Valagussa P; Bonadonna G Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571 [No Abstract] [Full Text] [Related]
7. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease. Brusamolino E; Lazzarino M; Morra E; Inverardi D; Merante S; Castelli G; Canevari A; Dornini G; Bernasconi C Haematologica; 1989; 74(2):173-9. PubMed ID: 2473013 [TBL] [Abstract][Full Text] [Related]
9. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578 [TBL] [Abstract][Full Text] [Related]
10. MOPP, ABVD, or both to treat Hodgkin's disease. Aisenberg AC N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765 [No Abstract] [Full Text] [Related]
11. Hodgkin's disease: controversies and challenges for the future. Tura S; Canellos G; Goldstone A; Longo D; McMillan A; Urba W; Zinzani PL Haematologica; 1991; 76(4):263-79. PubMed ID: 1724436 [No Abstract] [Full Text] [Related]
12. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study. Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131 [TBL] [Abstract][Full Text] [Related]
13. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease. Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235 [TBL] [Abstract][Full Text] [Related]
14. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496 [TBL] [Abstract][Full Text] [Related]
15. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773 [TBL] [Abstract][Full Text] [Related]
16. Pediatric Hodgkin's disease. Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795 [TBL] [Abstract][Full Text] [Related]
17. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. Busia A; Laffranchi A; Viviani S; Bonfante V; Villani F Anticancer Res; 2010 Oct; 30(10):4381-7. PubMed ID: 21036768 [TBL] [Abstract][Full Text] [Related]
18. Analysis of the risk of solid tumor following Hodgkin's disease. Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084 [TBL] [Abstract][Full Text] [Related]
20. Treatment of childhood Hodgkin's disease with chemotherapy alone. Experiences from the Royal Children's Hospital, Melbourne. Ekert H Cancer Treat Res; 1989; 41():241-6. PubMed ID: 2484293 [No Abstract] [Full Text] [Related] [Next] [New Search]